HC Wainwright restated their buy rating on shares of Evolus (NASDAQ:EOLS - Free Report) in a research note released on Friday,Benzinga reports. They currently have a $27.00 price target on the stock.
Several other analysts also recently weighed in on the stock. Barclays boosted their price objective on shares of Evolus from $20.00 to $22.00 and gave the stock an "overweight" rating in a research report on Monday, January 27th. Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Evolus in a research report on Tuesday, January 21st.
Read Our Latest Stock Report on EOLS
Evolus Stock Up 0.3 %
Evolus stock traded up $0.05 during trading on Friday, reaching $14.79. The stock had a trading volume of 500,423 shares, compared to its average volume of 923,868. Evolus has a 52-week low of $9.25 and a 52-week high of $17.82. The business has a 50 day moving average price of $12.13 and a 200 day moving average price of $14.00. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The stock has a market cap of $936.50 million, a PE ratio of -16.25 and a beta of 1.33.
Institutional Trading of Evolus
Several institutional investors have recently modified their holdings of EOLS. Tri Locum Partners LP acquired a new position in shares of Evolus in the 4th quarter valued at $8,198,000. Gilder Gagnon Howe & Co. LLC increased its holdings in shares of Evolus by 287.2% in the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company's stock valued at $7,753,000 after acquiring an additional 520,859 shares during the period. Caligan Partners LP increased its holdings in shares of Evolus by 22.7% in the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock valued at $29,724,000 after acquiring an additional 498,900 shares during the period. Allostery Investments LP acquired a new position in shares of Evolus in the 4th quarter valued at $4,760,000. Finally, Altium Capital Management LLC increased its holdings in shares of Evolus by 93.0% in the 4th quarter. Altium Capital Management LLC now owns 685,000 shares of the company's stock valued at $7,562,000 after acquiring an additional 330,000 shares during the period. Hedge funds and other institutional investors own 90.69% of the company's stock.
Evolus Company Profile
(
Get Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
See Also
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
